Enantioenriched 3-quinolyl alkanols act as asymmetric autocatalysts in the addition of diisopropylzinc to the corresponding substituted quinoline-3-carbaldehydes, to afford themselves with an amplified enantiomeric excess(ee) of up to 97%.
The addition of substituted anilines to ”vinamidinium" bis-tetrafluoroborate salt 1 [2-dimethylaminomethylene-1,3-bis(dimethylimmonio)propane bis-tetrafluoroborate], followed by cyclization of the resulting imino-eneamine salt and hydrolysis of the masked aldehydes 2, provide the corresponding 3-formyl quinolines 3. While the condensation of both 1 and its analogous bis-perchlorate salt and amidines are known to provide pyrimidines, we believe this is the first example of a quinoline annulation sequence with ”vinamidinium" bis-tetrafluoroborate salt 1 and anilines.
GATTI, R.;CAVRINI, V.;ROVERI, P.;MATTEUZZI, D.;BRIGIDI, P., EUR. J. MED. CHEM., 1984, 19, N 5, 468-474
作者:GATTI, R.、CAVRINI, V.、ROVERI, P.、MATTEUZZI, D.、BRIGIDI, P.
DOI:——
日期:——
[EN] ADAMANTANYL-(CYCLOPROPYL)-KETONES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS<br/>[FR] ADAMANTANYL-(CYCLOPROPYL)-CÉTONES UTILISÉES EN TANT QUE MODULATEURS DU RÉCEPTEUR MÉTABOTROPIQUE DU GLUTAMATE
申请人:MERZ PHARMA GMBH & CO KGAA
公开号:WO2008035049A1
公开(公告)日:2008-03-27
[EN] The invention relates to adamantyl-(cyclopropyl)-ketone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are Group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders. [FR] L'invention concerne des dérivés d'adamantyl-(cyclopropyl)-cétone ainsi que leurs sels acceptables sur le plan pharmaceutique. L'invention concerne également un procédé de préparation desdits composés. Les composés de l'invention sont des modulateurs du mGluR du groupe 1 et sont par conséquent utiles pour la lutte et la prévention contre les troubles neurologiques aigus et/ou chroniques.
Gatti; Cavrini; Roveri, European Journal of Medicinal Chemistry, 1984, vol. 19, # 5, p. 468 - 474